ALVO
Price
$4.54
Change
+$0.06 (+1.34%)
Updated
Nov 3 closing price
Capitalization
1.62B
8 days until earnings call
Intraday BUY SELL Signals
PRGO
Price
$15.68
Change
-$0.07 (-0.44%)
Updated
Nov 3, 04:59 PM (EDT)
Capitalization
2.19B
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALVO vs PRGO

ALVO vs PRGO Comparison Chart in %
View a ticker or compare two or three
VS
ALVO vs. PRGO commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALVO is a Buy and PRGO is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALVO with price predictions
Nov 02, 2026

ALVO's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for ALVO moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 27 of the 34 cases the stock moved higher. This puts the odds of a move higher at 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +6.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALVO as a result. In 77 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.

The Moving Average Convergence Divergence Histogram (MACD) for ALVO turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 35 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for ALVO entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.460) is normal, around the industry mean (8.029). P/E Ratio (-7.323) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

A.I.Advisor
a Summary for PRGO with price predictions
Nov 02, 2026

PRGO in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 15, 2026

PRGO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 30 similar instances where the stock broke above the upper band. In 24 of the 30 cases the stock fell afterwards. This puts the odds of success at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PRGO moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 20 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.

The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRGO as a result. In 55 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.

The Moving Average Convergence Divergence Histogram (MACD) for PRGO turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 27 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +4.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRGO advanced for three days, in 179 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 125 of 204 cases where PRGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.869) is normal, around the industry mean (8.029). P/E Ratio (-1.258) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (1.142) is also within normal values, averaging (2.152). Dividend Yield (0.074) settles around the average of (0.047) among similar stocks. P/S Ratio (0.454) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. PRGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

FUNDAMENTALS RATINGS
ALVO vs PRGO: Fundamental Ratings
ALVO
PRGO
OUTLOOK RATING
1..100
7581
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
8
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
5937
P/E GROWTH RATING
1..100
9889
SEASONALITY SCORE
1..100
7516

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRGO's Valuation (8) in the Pharmaceuticals Other industry is in the same range as ALVO (10) in the null industry. This means that PRGO’s stock grew similarly to ALVO’s over the last 12 months.

PRGO's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ALVO (100) in the null industry. This means that PRGO’s stock grew similarly to ALVO’s over the last 12 months.

PRGO's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as ALVO (100) in the null industry. This means that PRGO’s stock grew similarly to ALVO’s over the last 12 months.

PRGO's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as ALVO (59) in the null industry. This means that PRGO’s stock grew similarly to ALVO’s over the last 12 months.

PRGO's P/E Growth Rating (89) in the Pharmaceuticals Other industry is in the same range as ALVO (98) in the null industry. This means that PRGO’s stock grew similarly to ALVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALVOPRGO
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
64%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
63%
MACD
ODDS (%)
Bearish Trend 5 days ago
74%
Bearish Trend 2 days ago
66%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 7 days ago
74%
Bullish Trend 19 days ago
64%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
67%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
61%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (ALVO: $4.48 vs. PRGO: $15.75)
Brand notoriety: ALVO and PRGO are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALVO: 159% vs. PRGO: 76%
Market capitalization -- ALVO: $1.62B vs. PRGO: $2.19B
ALVO [@Pharmaceuticals: Generic] is valued at $1.62B. PRGO’s [@Pharmaceuticals: Generic] market capitalization is $2.19B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALVO’s FA Score shows that 1 FA rating(s) are green while PRGO’s FA Score has 1 green FA rating(s).

  • ALVO’s FA Score: 1 green, 4 red.
  • PRGO’s FA Score: 1 green, 4 red.
According to our system of comparison, PRGO is a better buy in the long-term than ALVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALVO’s TA Score shows that 3 TA indicator(s) are bullish while PRGO’s TA Score has 3 bullish TA indicator(s).

  • ALVO’s TA Score: 3 bullish, 6 bearish.
  • PRGO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, PRGO is a better buy in the short-term than ALVO.

Price Growth

ALVO (@Pharmaceuticals: Generic) experienced а -3.03% price change this week, while PRGO (@Pharmaceuticals: Generic) price change was -0.44% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.43%. For the same industry, the average monthly price growth was -7.19%, and the average quarterly price growth was +2.27%.

Reported Earning Dates

ALVO is expected to report earnings on Nov 11, 2026.

PRGO is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.43% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
ALVO
Daily Signal:
Gain/Loss:
PRGO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ALVO and

Correlation & Price change

A.I.dvisor tells us that ALVO and CRON have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and CRON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALVO
1D Price
Change %
ALVO100%
+1.34%
CRON - ALVO
24%
Poorly correlated
+1.50%
EBS - ALVO
23%
Poorly correlated
-2.95%
PAHC - ALVO
22%
Poorly correlated
-2.81%
ACB - ALVO
22%
Poorly correlated
+22.27%
LFCR - ALVO
21%
Poorly correlated
+0.47%
More

PRGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRGO has been loosely correlated with SUPN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PRGO jumps, then SUPN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRGO
1D Price
Change %
PRGO100%
-0.32%
SUPN - PRGO
49%
Loosely correlated
-22.41%
ELAN - PRGO
37%
Loosely correlated
+1.95%
PBH - PRGO
35%
Loosely correlated
-0.38%
EVO - PRGO
35%
Loosely correlated
+1.97%
ALVO - PRGO
34%
Loosely correlated
+1.34%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GRAN1.200.04
+3.45%
Grande Group Ltd
LBRX40.331.29
+3.30%
LB Pharmaceuticals Inc
DSP12.960.24
+1.89%
Viant Technology
DLB63.320.04
+0.06%
Dolby Laboratories IncClass A
ICE170.93-1.35
-0.78%
Intercontinental Exchange